Loading...
Market
FDA approval status of Roche's obesity drug by end of 2025
5
Resolution / Starting Odds
Approved without restrictions • 40%
Approved with specific conditions • 40%
Not approved • 20%
FDA announcements or Roche press releases
Story
Roche's Obesity Drug Shows Positive Phase I Results, Shares Rise 4.7% After 18.8% Weight Loss
May 16, 2024, 09:25 AM
Roche has reported positive Phase I results for its experimental obesity drug, developed by newly acquired Carmot Therapeutics. The trial showed an average weight loss of approximately 18.8%, leading to a 4.7% increase in Roche shares at the market open on Thursday. The company described the results as 'encouraging' amidst growing competition in the obesity drug market. This marks the first clinical readout since Roche acquired Carmot Therapeutics for $2.7 billion.
View original story
Similar markets
Yes • 50%
No • 50%
Phase 3 trial initiation • 25%
Phase 3 trial results • 25%
FDA filing • 25%
FDA approval • 25%
